Objective We identified the prognostic relevance of pneumothorax in interstitial lung disease (ILD) patients and evaluated the efficacy and safety of autologous blood-patch pleurodesis. Methods We retrospectively reviewed 59 occurrences of pneumothorax in 34 ILD patients identified over a 12-year period. Results Air leakage ceased in 16 of 22 (72.7%) episodes after blood pleurodesis and in 11 of 14 (78.6%) episodes after chemical pleurodesis. Both the cure ratio and recurrence ratio in the cure episodes were comparable with those in the chemical pleurodesis group (p=0.99 and 0.99, respectively). In addition, there were no harmful events associated with blood pleurodesis. The median survival time after the first episode of pneumothorax was less than 9 months in patients with idiopathic interstitial pneumonia (IIP) and only around 3 years in the patients with other types of ILD, which have essentially favorable outcomes. Kaplan-Meier survival estimates were significantly worse in the patients with concomitant pneumomediastinum than in those without (p<0.05). A multivariate Cox regression analysis identified that the number of episodes of pneumothorax, IIP diagnosis and concomitant pneumomediastinum were independent predictors of death. Conclusion Autologous blood-patch pleurodesis is safe and worth considering as a first-line treatment for pneumothorax secondary to ILD. However, despite treatments, the prognosis after the onset of pneumothorax in ILD patients was found to be poor. In addition, concomitant pneumomediastinum may further worsen the prognosis.
Introduction
Spontaneous pneumothorax is a relatively frequent complication in some types of interstitial lung disease (ILD), namely idiopathic pulmonary fibrosis (IPF) (1-3), sarcoidosis (4), pulmonary Langerhans' cell histiocytosis (5) and lymphangioleiomyomatosis (6) . The underlying mechanism of pneumothorax in such diseases is considered to be the result of the rupture of acquired subpleural cystic spaces related to diffuse interstitial fibrosis (2, 4, 6) . In ILD patients, the distinctive rigidity of lung parenchyma may inhibit reexpansion of the lung. Corticosteroids, which are a frequently-used drug for ILD, may inhibit healing of the injured lung and may cause persistent air leak (7) . Moreover, pneumothorax in ILD usually results from progression of underlying disease. Therefore, secondary spontaneous pneumothorax in ILD patients often presents as a difficult-totreat disease and prognosis after the onset of pneumothorax is predicted to be poor. The latest British Thoracic Society guideline recommends surgical intervention as a treatment option in such patients when an air leak persists for 48 hours (8) . However, because of the severity of their underlying disease, these patients are often not strong enough to make good candidates for surgical treatment, and as a consequence their optimal management is challenging.
For pneumothorax patients who are not good candidates for surgical treatment, chemical pleurodesis has been reported and accepted as a treatment (9) (10) (11) (12) (13) . However, chemical pleurodesis is ineffective when the lungs of the patients are deflated. Moreover, it can contribute to the onset of acute exacerbation of idiopathic pulmonary fibrosis (14, 15) . As an alternative, autologous blood-patch pleurodesis has been used for the treatment of primary and secondary pneumothorax (16) (17) (18) (19) (20) (21) . The injection of autologous blood into the pleural space is a simple, safe, and inexpensive treatment for pneumothorax and is available not only in patients with persistent air leak but also in those with residual air space (18) . However, there have been no reports which have compared the efficacy and safety between the two methods of pleurodesis in patients with pneumothorax secondary to ILD.
In our institute, prior to 2000, chemical pleurodesis was used as first-line treatment for pneumothorax in ILD patients with persistent air leak. However, since 2001, and based on previous reports (14, 18, 20) , we have switched to using autologous blood-patch pleurodesis as first-line treatment in these patients. The aim of this study was to evaluate the efficacy and safety of autologous blood-patch pleurodesis in ILD patients.
Methods

Patients
A retrospective review was carried out of the medical records of all patients with ILD who were admitted to the Respiratory Division of Kyoto University Hospital for pneumothorax between December 1997 and August 2009. A total of 59 occurrences of pneumothorax in 34 ILD patients were identified over this 12-year period. Clinical data and survival status after the first episode of pneumothorax were obtained from these medical records. Patients with idiopathic interstitial pneumonia (IIP) were diagnosed on the basis of the American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the IIPs (22) . The medical ethics committee at our institution reviewed and approved the study.
Blood and chemical pleurodesis
If an air leak had not ceased within 2 days under tube thoracostomy, we conducted autologous blood-patch or chemical pleurodesis on the patients who were not good candidates for surgery. As mentioned above, chemical pleurodesis was used in our institute as the first-line treatment of choice up to the end of 2000; however, since that time autologous blood-patch pleurodesis has replaced this procedure as the first-line treatment. Autologous blood-patch pleurodesis was performed according to the previously described method (17, 20) . Briefly, 50 mL of autologous blood without anticoagulant was obtained from each patient. As soon as the blood was drawn from the patient, it was immediately injected into the pleural space through a doublelumen chest tube. The connected tube was then elevated 60 cm above the patient and left to water-seal or to be continuously aspirated with negative pressure for 2 hours. During this period, the patient was asked to change their position in bed every 15 minutes. Thereafter, the drain tubing support was removed. Chemical pleurodesis was induced with either minocycline (minomycin), 200 mg in 50 mL isotonic saline, or OK432 (picibanil) 10 KE in 50 mL isotonic saline. The solutions were instilled into the pleural space through a double-lumen chest tube. After instillation, the chest tube was clamped for 2 hours. During this period, the patient was asked to change their position in bed every 15 minutes.
In cases where the air leak continued for more than 2 days or reappeared within 1 week after pleurodesis, the physicians chose to carry out surgery or to repeat the autologous blood or sclerotic agent infusions once more. In cases where the air leak stopped within 2 days of the pleurodesis, and no recurrence of pneumothorax was observed for more than 1 week, the procedure was judged to have been effective.
Statistics
All statistical analyses were performed using StatView version 5.0 for Windows (Abacus Concepts, Berkeley, CA, USA). Continuous variables are expressed as medians (range). Fisher's exact probability test was used to compare dichotomous variables and Mann-Whitney's U-test was used to compare continuous data between the 2 groups. Survival curves were obtained using Kaplan-Meier's method. The significance was obtained by a log-rank test. Mortality was first assessed for all risk factors using univariate analysis. Near significant predictors of death (p<0.1) were included into a multivariate Cox regression analysis to identify significant independent predictors of cumulative mortality for all patients. A p value less than 0.05 was considered to indicate statistical significance.
Results
Demographic features of the subjects
Demographic data are presented in Table 1 . The study group of 34 patients consisted of IIPs (n=17), sarcoidosis (n=6), collagen vascular disease (n=7, of which rheumatoid arthritis [n=2], systemic sclerosis [n=4], and systemic lupus erythematosus [n=1]), berylliosis (n=1), chronic hypersensitivity pneumonitis (n=1), pulmonary Langerhans' cell histiocytosis (n=1) and drug-induced pneumonia (n=1). Four patients had undergone surgical lung biopsy before the first episode of pneumothorax. The 17 IIP cases comprised 9 UIP patients (histological diagnosis 1 patient and clinical diagnosis 8 patients) and 8 non-UIP patients without surgical lung biopsy. The high-resolution computed tomography (HRCT) findings of the 8 non-UIP patients without surgical lung biopsy showed bilateral and lower lung dominant traction bronchiectasis that was compatible with a nonspecific interstitial pneumonia (NSIP) pattern (23) . Three patients (8.8%) were current smokers and approximately a quarter (23.5%) were receiving domiciliary oxygen therapy. In 17 patients (50%), pneumothorax occurred more than once during the follow-up period. Before the onset of pneumothorax (and pneumomediastinum), 10 patients (29.4%) had been taking corticosteroids (9 [5-70] mg of prednisolone equivalent) for 14 (1-158) months. Concomitant pneumomediastinum was revealed in 7 (20.6%) out of 34 patients. Patients with concomitant pneumomediastinum had been treated with corticosteroids more frequently than those without (5 out of 7 patients vs 5 out of 27 patients, p=0.006).
Treatment for pneumothorax and its outcome
As the first-line treatment, autologous blood-patch pleurodesis was carried out in 22 episodes, chemical pleurodesis was carried out in 9 episodes and surgery was performed in 3 episodes of pneumothorax with persistent air leak. In 25 episodes (42.4%), the patients were observed without intervention. As the second-or third-line treatment, chemical pleurodesis was carried out in 5 episodes and surgery was performed in 2 episodes. The results of each treatment are summarized in Table 2 . Air leakage ceased in 16 (72.7%) episodes with pneumothorax after blood pleurodesis and in 11 (78.6%) episodes after chemical pleurodesis. The response rate to blood pleurodesis was comparable with chemical pleurodesis (p=0.99). Recurrence of pneumothorax occurred in 8 (50.0%) episodes after blood pleurodesis and in 5 (45.5%) episodes after chemical pleurodesis. The recurrence rate in the blood pleurodesis group was also comparable with the chemical pleurodesis group (p=0.99). The time to recurrence after cessation of air leak was not statistically different between groups (p=0.61). There were no respiratory complications after autologous blood-patch pleurodesis. However, some respiratory complications developed in 2 patients (14.3%) who underwent chemical pleurodesis, including one case each of acute exacerbation of idiopathic pulmonary fibrosis and asthma attack.
Prognosis and predictors of death after the onset of pneumothorax
During a mean follow-up period of 15 (1-127) months, 24 of the 34 patients died. The median survival time of all patients after the first episode of pneumothorax was 18.8 months. The major cause of death was respiratory failure due to the progression of underlying disease. One patient died of lung cancer and 2 died of pulmonary aspergillosis. Two patients died suddenly at home from an unknown cause. Kaplan-Meier survival was significantly worse in IIP patients than in other ILD patients (p=0.004, log-rank test): median survival times were 8.6 months and 38.7 months, respectively. However, in IIP patients, there was no difference in Kaplan-Meier survival estimates between IPF and non-IPF (p=0.50, log-rank test). Kaplan-Meier survival was also significantly worse in the patients with concomitant pneumomediastinum than in those without (p=0.048, log-rank test): median survival times were 7.4 months and 21.8 months, respectively (Fig. 1) . There was no difference in Kaplan-Meier survival estimates between patients treated up to 2000 and those treated since 2001 (p=0.33, log-rank test).
When predictors of death after the onset of pneumothorax for all ILD patients were assessed, age at the onset of pneumothorax, number of episodes of pneumothorax, IIP diagnosis and concomitant pneumomediastinum were significantly associated with an increased risk of death on univariate analysis (Table 3) . A multivariate Cox regression analysis identified that the number of episodes of pneumothorax, IIP diagnosis and concomitant pneumomediastinum were independent predictors of death.
Discussion
Secondary spontaneous pneumothorax in ILD is refractory and life-threatening because of the compromised lung function. Since 2001, we have been using autologous bloodpatch pleurodesis as the first-line treatment of choice for this condition and its effectiveness was comparable to chemical pleurodesis. However, despite this and other treatments for pneumothorax, the prognosis after the onset of pneumothorax is poor, particularly in patients with IIP.
Autologous blood-patch pleurodesis was first described by Robinson in 1987 (16) and has been used since for the treatment of primary and secondary pneumothorax (19, 20) . Its mechanism of action is thought to be the direct sealing of the air leak by coagulated blood as well as functioning as a true pleurodesis (17, 21) and it can be employed even if the lung is not fully expanded (18) . Therefore, it is an easily applied treatment for pneumothorax, even in patients with less compliant lungs, such as seen in ILD. Although empyema (19) and blood clotting in the tube (24) have been reported as complications of blood pleurodesis, no harmful event occurred with the procedure in the present study. Chemical pleurodesis is an accepted treatment for secondary spontaneous pneumothorax (9-13). However, chemical pleurodesis is ineffective when the lungs of the patients are deflated. Moreover, it can contribute to the onset of acute exacerbation of idiopathic pulmonary fibrosis (14, 15) . In the present study, an acute exacerbation of idiopathic pulmonary fibrosis occurred after instillation of sclerotic agent in one patient and played a leading role in his death.
In the blood pleurodesis group, both the cure ratio and recurrence ratio were comparable with those in the chemical pleurodesis group. In addition, there were no harmful events associated with blood pleurodesis. In ILD patients, the occurrence of an acute exacerbation is fatal (25, 26) and despite tube drainage, the injured lung is often deflated until air leakage ceases. Therefore, autologous blood-patch pleurodesis is worthy of consideration for the first-line treatment of pneumothorax with persistent air leak in ILD patients.
Due mainly to worsening of underlying disease, the median survival time after the first episode of pneumothorax in IIP patients was less than 9 months. Although it has been reported that patients with IPF have a worse survival than patients with other types of IIPs including NSIP (27) , the prognosis after the onset of pneumothorax was equally poor among these diseases. Moreover, even in the patients with other ILD, which have essentially favorable outcomes, the median survival time after the first episode of pneumothorax was only around 3 years. Therefore, the occurrence of pneumothorax in IIP patients may have resulted not only from the compromised pulmonary function but also from the rapid progression of the underlying disease. Although the total number of episodes of pneumothorax was negatively correlated with mortality, it is likely that the number of episodes was not the cause of death but the result of prolonged survival.
In addition, the patients with concomitant pneumomediastinum had a worse prognosis than those without. It is noteworthy that the majority of the patients with concomitant pneumomediastinum were receiving corticosteroids for underlying lung disease. Matsuoka et al. reviewed computed tomography images before and at the time of detection of pneumomediastinum in patients with ILD and reported that pneumomediastinum had developed in the patients receiving corticosteroids despite the decrease of lung opacities including ground-glass opacity and consolidation (28) . Therefore, corticosteroid use may be associated with the development of pneumomediastinum. Fujiwara et al. reported that 4 out of 5 patients with pulmonary fibrosis and pneumomediastinum had died within 6 months of the detection of pneumomediastinum (29) . According to the result of the present study, pneumomediastinum may be a prognostic factor in patients with pneumothorax secondary to ILD. In the patients with IPF, corticosteroids have little efficacy and their rapid tapering seems to be associated with acute exacerbation (30, 31) . If corticosteroid use can worsen the prognosis via development of pneumomediastinum, treatment with corticosteroids should be avoided in such patients as only a minimal response is expected. Although patients with concomitant pneumomediastinum had been treated with corticosteroids more frequently than those without, corticosteroid use was not an independent predictor of death. This result might be due partly to the fact that the sample size of our study was insufficient to detect any statistical significance.
The present study has some methodological limitations. The main limitation was the retrospective design and small sample size. Furthermore, there was no consistency in the second-line treatment administered for pneumothorax as this depended on the individual physician. Therefore, a large, prospective study is needed to confirm our findings. The second point was the lack of control groups. We could not compare the prognosis of ILD patients based on the presence or absence of pneumothorax and also could not evaluate the risk factors for development of pneumothorax. However, prognosis after the onset of pneumothorax in IIP patients was less than half the mean survival time after the prescription of long-term home oxygen therapy in patients with the same disorder (32) . In our study population, there were predominant subpleural cystic lesions not only in the patients with IPF but also in the patients with non-IPF IIP or other ILDs. It seems quite likely that these predominant cystic lesions were associated with the development of pneumothorax. Thirdly, pulmonary function tests around the time of onset of pneumothorax could only be performed in less than 50% of subjects, and accordingly, disease severity of each patient was not taken into consideration in Cox regression analysis. However, even in a prospectively designed study, it would be difficult to perform pulmonary function tests under thoracostomy or shortly after the resolution of pneumothorax in such patients.
In conclusion, autologous blood-patch pleurodesis can be safely performed for the treatment of pneumothorax in patients with ILD. The effectiveness of this procedure was comparable to that of chemical pleurodesis and appears to be worth consideration for the first-line treatment of pneumothorax with persistent air leak in ILD patients. However, the prognosis after the onset of pneumothorax is poor and concomitant pneumomediastinum may further worsen prognosis.
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